BioSpace News Archive

Biotech Beach

Xencor to Present at Upcoming November 2022 Investor Conferences

Xencor, Inc. announced that company management will participate at two upcoming investor conferences.

November 10, 2022
·
1 min read
Business

Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

November 10, 2022
·
11 min read
Business

Agiliti Announces Financial Results for Third Quarter 2022

Agiliti Inc., a nationwide provider of healthcare technology management and service solutions to the United States healthcare industry, announced its financial results for the quarter ended September 30, 2022, and revised its full-year financial guidance.

November 10, 2022
·
16 min read
Business

Paragon 28 Reports Third Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, reported financial results for the quarter ended September 30, 2022 and increased its 2022 net revenue guidance.

November 10, 2022
·
13 min read
Business

Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the quarter ended September 30, 2022.

November 10, 2022
·
13 min read
Business

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2022 and provided a business update.

November 10, 2022
·
8 min read
Business

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate updates.

November 10, 2022
·
12 min read
Business

Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced financial results for the quarter ended September 30, 2022, and provided a corporate update.

November 10, 2022
·
13 min read
Business

Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update

Histogen Inc. (NASDAQ: HSTO) today reported financial results for the third quarter ended September 30, 2022 and provided an update on its clinical pipeline and other corporate developments.

November 10, 2022
·
10 min read
Business

Panbela Provides Business Update and Reports Q3 2022 Financial Results

Panbela Therapeutics, Inc. (Nasdaq: PBLA) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2022.

November 10, 2022
·
13 min read